Streetbeat News

Analyst Ratings

PYPL

A significant amount of unusual options activity has been observed for PayPal Holdings (NASDAQ:PYPL), indicating a bullish stance by a large investor or institution. The overall sentiment of these big-money traders is split between 56% bullish and 43% bearish. The whales have been targeting a price range from $60.0 to $145.0 for PayPal Holdings over the last 3 months. Truist Securities and Piper Sandler have maintained their Buy and Neutral ratings on PayPal Holdings, respectively, with a price target of $80.

Portfolio Pulse from Benzinga Insights

July 14, 2023 | 7:04 pm

MU

A significant number of unusual options trades have been detected for Micron Technology (NASDAQ:MU), with 52% of investors showing bullish expectations and 48% bearish. The trades include 9 puts totaling $765,628 and 16 calls totaling $684,065. Whales have been targeting a price range from $57.5 to $75.0 for Micron Technology over the last 3 months. The current price of MU is $64.4, down 0.2%. Analysts from Goldman Sachs, TD Cowen, and Barclays maintain positive ratings on Micron Technology, while Citigroup and Morgan Stanley have downgraded their ratings.

Portfolio Pulse from Benzinga Insights

July 14, 2023 | 7:04 pm

ALHC

Alignment Healthcare (NASDAQ:ALHC) has received mixed analyst ratings in the last quarter, with 1 bullish, 2 somewhat bullish, and 2 indifferent ratings. The average 12-month price target for the company is $11.2, representing a 15.47% decrease from the previous average price target of $13.25.

Portfolio Pulse from Benzinga Insights

July 14, 2023 | 7:01 pm

CHRS

In the last quarter, Coherus BioSciences (NASDAQ:CHRS) received 9 bullish and 1 somewhat bullish ratings from analysts. The company's average 12-month price target is $21.6, an increase of 1.65% from the previous average of $21.25.

Portfolio Pulse from Benzinga Insights

July 14, 2023 | 7:01 pm

MCD

In the last quarter, McDonald's (NYSE:MCD) has received 25 analyst ratings, with the majority being bullish. The average price target for the stock is $320.32, which is higher than the current price of $295.29. This average has increased by 5.35% from the previous average price target of $304.05.

Portfolio Pulse from Benzinga Insights

July 14, 2023 | 7:01 pm

OSCR

Over the past 3 months, 5 analysts have published their opinion on Oscar Health (NYSE:OSCR) stock. According to these analysts, Oscar Health has an average price target of $8.25 with a high of $12.00 and a low of $5.00. This average price target has increased by 30.33% over the past month.

Portfolio Pulse from Benzinga Insights

July 14, 2023 | 7:00 pm

W

Wayfair (NYSE:W) has received 12 analyst ratings in the last quarter, with the majority being bullish. The average price target is $63.17, which is lower than the current price of $69.15, implying a downside. The average price target has increased by 6.04% from the previous average of $59.57.

Portfolio Pulse from Benzinga Insights

July 14, 2023 | 7:00 pm

WBA

Walgreens Boots Alliance (NASDAQ:WBA) has received mixed analyst ratings in the last quarter, with 9 indifferent, 1 somewhat bullish, and 1 somewhat bearish. The average price target is $33.91, implying an upside from the current price of $29.22. However, this average has decreased by 16.62% from the previous average price target of $40.67.

Portfolio Pulse from Benzinga Insights

July 14, 2023 | 7:00 pm

THRX

Theseus Pharmaceuticals Inc (NASDAQ:THRX) shares plummeted after the company announced discontinuation of enrollment in a phase 1/2 study and termination of the development of THE-630 for gastrointestinal stromal tumors due to dose-limiting toxicities. Analysts from Cantor Fitzgerald, Needham, Wedbush, and HC Wainwright have cut their price targets but remain optimistic about the company's platform. The company is considering developing low-dose THE-630 for KIT-associated mast cell-driven inflammatory indications.

Portfolio Pulse from Vandana Singh

July 14, 2023 | 6:59 pm

VITL

Needham analyst Matt McGinley reiterated a Hold rating on Vital Farms Inc (VITL), predicting single-digit volume growth due to bird flu induced supply shortage. The analyst estimates Q2 sales growth of 27% y/y to $105 million, driven by a combination of price and volume gains. However, concerns regarding volume growth have sent the stock down by over 25% since early May.

Portfolio Pulse from Shivani Kumaresan

July 14, 2023 | 6:57 pm